This article is more than 5 years old. Information may no longer be current.

First patient treated in Salutaris brachytherapy device trial for AMD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The first patient has been treated in a clinical trial of an ophthalmic brachytherapy device for neovascular age-related macular degeneration, Salutaris Medical Devices announced in a press release.

Principal investigator Gregg Kokame, MD, successfully performed the procedure with the SMD-DA device on May 9 in Honolulu.

The prospective, single-arm, open-label study is evaluating the safety and tolerability of the SMD-DA system concomitant with an anti-VEGF treatment regimen in 20 patients; surgeon ease of use will also be determined.

“Our hope is to provide improved outcomes to the growing number of patients suffering from neovascular age-related macular degeneration, many of whom do not respond well to existing treatments. There is a great potential for real quality of life improvements,” Ryan Lohrenz, SalutarisMD CEO, said in the release.